Recordkeeping fees per participant
not reported
Not reported on this filing.
Employers › Crispr Therapeutics
Crispr Therapeutics 401(k)
- CRSP Nasdaq
- Professional, scientific, and technical services
- Boston, MA
- EIN 47-3173478
- 1 plan with Schedule H financials
- Plan year 2024
- Crispr Therapeutics AG
- filed as Crispr Therapeutics, Inc.
- SEC registrant CRISPR Therapeutics AG
Filed as negative.Schedule H line 2i(12) is reported as -$99,382; Schedule H line 2i(3) is reported as -$122,977. The filing is shown as received; the derived figures below treat a negative amount as zero, and a percentile is only shown for positive values.
Total assets, end of year · Crispr Therapeutics 401(k) Retirement Plan · plan year 2024
$66,700,833
609 participants with a balance. This filing reports no recordkeeping fee and no administrative expenses excluding investment management, so there is no headline cost figure.
Source
Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250919092209NAL0002501760001, received 2025-09-19
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250919092209NAL0002501760001, received 2025-09-19
Percentiles compare this plan with the Schedule H plans $50 to 250M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-09-19.
Cost and contributions
Administrative expenses excluding investment management, per participant
$0.00
Fewer than 50 comparable plans report this figure; no percentile.
Source
= $0 / 609
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250919092209NAL0002501760001, received 2025-09-19
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250919092209NAL0002501760001, received 2025-09-19
Administrative expenses per participant
filed as negative
Filed as a negative amount; no comparison.
Administrative expenses as a share of assets
filed as negative
Filed as a negative amount; no comparison.
Employer contributions per participant
$4,351
Higher than 72% of the 9,105 plans $50 to 250M that report it.
Source
= $2,649,653 / 609
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250919092209NAL0002501760001, received 2025-09-19
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250919092209NAL0002501760001, received 2025-09-19
Employer share of total contributions
26.6%
Higher than 40% of the 9,112 plans $50 to 250M that report it.
Source
= $2,649,653 / $9,946,138
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250919092209NAL0002501760001, received 2025-09-19
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250919092209NAL0002501760001, received 2025-09-19
Plan terms, as stated in Crispr Therapeutics AG's SEC filings
Plan terms are described in Crispr Therapeutics AG's SEC filings: Form 10-K filed 2026-02-12. No term could be quoted from them with the required precision.
Plan features
2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2S pre-approved plan document · 2T default investment (QDIA) · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20250919092209NAL0002501760001, received 2025-09-19
Full record, Crispr Therapeutics 401(k) Retirement Plan
| Field | Value | Source |
|---|---|---|
| Plan sponsor | CRISPR THERAPEUTICS, INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Plan name | CRISPR THERAPEUTICS 401(K) RETIREMENT PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Sponsor EIN / plan number | 47-3173478 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Sponsor location | BOSTON, MA | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Industry (business code) | 541700, Professional, scientific, and technical services | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Filing received | 2025-09-19 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Participants, beginning of year | 630 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Active participants | 398 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Participants, end of year | 618 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Participants with an account balance | 609 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Total assets, beginning of year | $53,817,882 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Total assets, end of year | $66,700,833 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Net assets, end of year | $66,700,833 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Total income | $18,717,196 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Net income | $12,882,951 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Employer contributions | $2,649,653 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Participant contributions | $6,239,570 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Other contributions (incl. rollovers) | $1,056,915 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Total contributions | $9,946,138 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Benefit payments | $5,931,682 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Total expenses (incl. benefit payments) | $5,834,245 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Total administrative expenses | -$99,382 (filed as negative) | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Contract administrator fees | $0 | Schedule H, line 2i(2); CONTRACT_ADMIN_FEES_AMT pos 106; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Recordkeeping fees | -$122,977 (filed as negative) | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| IQPA audit fees | $0 | Schedule H, line 2i(4); IQPA_AUDIT_FEES_AMT pos 161; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Investment advisory and management fees | $23,595 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Administrative expenses excluding investment management | $0 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Held in master trusts | $0 | Schedule H, line 1c(11) col (b); INT_MASTER_TR_EOY_AMT pos 53; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Held in common/collective trusts | $749,388 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Held in mutual funds | $65,732,935 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20250919092209NAL0002501760001, received 2025-09-19 |
| Independent auditor | BAKER NEWMAN NOYES | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20250919092209NAL0002501760001, received 2025-09-19 |
Position = column in the DOL layout for form year 2024. Filing 20250919092209NAL0002501760001, received 2025-09-19.
Service providers paid directly by the plan
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| STRATEGIC ADVISORS, INC. | ADVISOR | 27 Investment advisory (plan) | $23,595 | no |
| FIDELITY INVESTMENTS INSTITUTIONALrecordkeeper | RECORDKEEPER | 37 Participant loan processing; 60 Sub-transfer agency fees; 64 Recordkeeping fees; 65 Account maintenance fees | $-122,977 | yes |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20250919092209NAL0002501760001, received 2025-09-19.
What changed since the 2023 plan year
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $53,817,882 | $66,700,833 | 23.9% |
| Participants with a balance | 624 | 609 | -2.4% |
| Administrative expenses | $-72,843 | $-99,382 | |
| Recordkeeping fees per participant | not reported | not reported | |
| Employer contributions | $2,907,211 | $2,649,653 | -8.9% |
Prior filing 20241002081349NAL0004664179001, received 2024-10-02; the plan years are contiguous.
Alerts, claims and corrections
Sponsor name as filed: CRISPR THERAPEUTICS, INC.; SEC registrant: CRISPR Therapeutics AG (CIK 1674416, matched by EIN; display name from the Form 10-K cover).